In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

Researchers studied the relationship between 3 dermatological immune-mediated inflammatory diseases and COVID-19.

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Discover how psoriasis affects immune function and the role of SSAT1 in this chronic skin condition. Learn more now.

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

How the Mediterranean diet’s transformative power fights stubborn skin disorders—discover the science-backed strategies ...

A systematic review revealed that patients with psoriasis have a significantly higher prevalence of onychomycosis than those without psoriasis.

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Some evidence suggests a higher risk of liver disease with psoriasis. Certain psoriasis treatments can cause liver toxicity, but the two conditions also share common risk factors, which may ...

Whether you’re just starting psoriasis treatment or are looking for more effective therapies for your symptoms, it helps to remember these important steps to take — and to avoid. If you’re ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...